A2V, a novel bevacizumab-based bispecific human IgG1 antibody that targets Ang2 and VEGFA, has been found to promote anti-tumor immunity by activating tumor-infiltrating CD8+ T cells, increasing tumor antigen presentation, and enhancing perivascular T-cell accumulation152. This evidence concerns the gene CD8A and neoplasm.